Compare iShares 10 20 Year Treasury Bond ETF (TLH) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 10 20 Year Treasury Bond ETF vs Zoetis Inc — how do they compare? iShares 10 20 Year Treasury Bond ETF trades at $92.23 (market cap $11.02B), while Zoetis Inc trades at $74.76 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 2.7× iShares 10 20 Year Treasury Bond ETF's market cap, and Zoetis Inc pays a 2.9% dividend while iShares 10 20 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares 10 20 Year Treasury Bond ETF for 60 Days and Zoetis Inc for 70 Days on average.
| TLH | ZTS | |
|---|---|---|
Market Cap | $11.02B | $30.20B |
Volume | 6,609,157 | 6,175,327 |
Sector | Fixed Income | Health |
52-Week High | $105.36 | $147.53 |
52-Week Low | $91.34 | $69.09 |
Typical Hold Time | 60 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TLH, an iShares 10-20 Year Treasury Bond ETF, trades at $92.19, up 0.81% on the day. The technical outlook is bearish based on moving averages, with neutral oscillators. Recent news highlights a challenging bond market environment, with Treasury yields reaching multi-decade highs, driving increased trading volume in the ETF. The fund continues its dividend distributions, with recent payments around $0.36-$0.38 per share.
The outlook for TLH is heavily influenced by the trajectory of long-term interest rates. Rising yields pressure bond prices, presenting headwinds, though the ETF offers income via dividends. Key risks include further Fed tightening and persistent inflation. Investors should weigh the income stability against potential capital depreciation in a rising rate environment.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
